BORTEZOMIB-INDUCED DILATED CARDIOMYOPATHY – MYTH OR REALITY?

Authors

  • Palaniappan Manickam Wayne State University/ Detroit Medical Center and Crittenton Hospital
  • Maithili Shenoy Wayne State University/ Detroit Medical Center
  • Indryas Woldie Wayne State University/ Detroit Medical Center
  • Pawan Hari Loma Linda University
  • Tushar Tuliani Wayne State University/ Detroit Medical Center
  • Timothy Byrnes

Abstract

(This article may be cited as Manickam Palaniappan, Shenoy Maithili, Woldie Indryas , Hari Pawan, Tuliani Tushar, Byrnes Timothy. Bortezomib-induced Dilated cardiomyopathy – Myth or Reality E-Journal of cardiology 2011;1(1):40-44.)

Introduction:

Bortezomib is a chemotherapeutic agent that was approved by the FDA for the treatment of multiple myeloma. Cardiomyopathy is a little known complication of Bortezomib use that has been reported on rare occasions. However, the cause of this association remains unknown.

Methods:

We present a case of dilated cardiomyopathy in a patient with multiple myeloma after receiving six cycles of Bortezomib and dexamethasone chemotherapy. Considering the time-period of events and normal pre-treatment echocardiogram, we hypothesize that the severe reduction in EF is most likely related to Bortezomib therapy.

Conclusion:

Although, there is no evidence of causal association, the possibility of myocardial damage should be considered in patients receiving Bortezomib.

Downloads

Published

2011-12-20

Issue

Vol. 1 No. 1 (2011): E-Journal of Cardiology

Section

Brief Reports